Deutsche Krebshilfe
HELFEN. FORSCHEN. INFORMIEREN.

Stiftung Deutsche Krebshilfe

Dr. h.c. Fritz Pleitgen
Präsident

Spendenkonto
Kreissparkasse Köln
IBAN DE65 3705 0299 0000 9191 91
BIC COKSDE33XXX

Priority Program: 'Translational Oncology'

Applicants' Guidelines for
Letter of Intent / Project Outlines

Introduction

The major goal of German Cancer Aid's funding program for the development of 'Interdisciplinary Oncology Centers of Excellence' ('Onkologische Spitzenzentren') in Germany is to continuously improve the treatment and care of cancer patients. Conducting interdisciplinary research programs that encompass both basic science as well as the essential translation of scientific findings into clinical practice is therefore an essential task of 'Interdisciplinary Oncology Centers of Excellence'. Patients can then rapidly benefit from new scientific progress. The following program for 'Translational Oncology' is another step in reaching this goal.

With the goal of further supporting collaborative translational cancer research projects at 'Interdisciplinary Oncology Centers of Excellence' and Comprehensive Cancer Centers, the German Cancer Aid has decided to launch a fifth call for applications within the funding program 'Translational Oncology'. Applications may submitted for a collaborative scientific project ('Verbundprojekt'), a combination of a collaborative scientific project and a clinical trial (Phase I/II) or an innovative clinical trial (Phase I/II). The projects/clinical trial must be performed at least at 3 sites and necessitate close collaboration between several research groups. At least one research group must be located at an 'Interdisciplinary Oncology Center of Excellence' funded by the German Cancer Aid. The maximal budget for this fifth call is 7 million Euros.

General Comments/Procedure:

We wish to point out that applications are not accepted from members of profit-making organizations or from persons not permitted to publish results in a generally accessible form.

The application and evaluation procedure takes place in three steps: Applicants must inform the German Cancer Aid by **January 2, 2018**, 13:00 that they plan to submit an application (Letter of Intent). Project outlines must be submitted no later than **February 14, 2018**, 13:00. If the preliminary evaluation is favorable, full applications must be submitted by **July 10, 2017**, 13:00. **Please submit all required printed documents by post/courier (not by e-mail or fax) to the offices of the German Cancer Aid. Please note: only the date and time of receipt in our offices (receipt stamp) is valid and not the postmark.**

The project outlines and applications submitted will be evaluated by an international committee of experts. For this reason, all project outlines and applications must be in English. The requirements for project outlines are described in detail in the following sections.

Please submit all required documents in writing by post to the office of the Deutsche Krebshilfe:

Deutsche Krebshilfe e. V.
Abteilung Förderung
Buschstraße 32
53113 Bonn

Letters of intent, project outlines and full applications **may not be sent by e-mail or fax**.

Within two weeks of receipt of the letters of intent, project outlines and full applications by the Deutsche Krebshilfe Office, the lead applicant will receive a written confirmation of receipt. If you fail to receive confirmation of receipt, please send an email to the Funding Department of the Deutsche Krebshilfe (foerderung@krebshilfe.de), giving the full project title and your telephone number.
If you have any questions, please contact:
Dr. Matthias Serwe, 0228 / 729 90-223, e-mail: serwe@krebshilfe.de
Kim Tiede, 0228 / 729 90-217, e-mail: tiede@krebshilfe.de
Dr. Laura Planko, 0228 / 729 90-224, e-mail: planko@krebshilfe.de

A. Guideline for Letter of Intent

1. Applicants
The following information is needed for the lead and co-applicants. Please give the name of the lead applicant, who is responsible for all co-applicants and for correspondence with the Deutsche Krebs-hilfe first:

- First name, surname, academic degree
- Full name of the institution at which the coordinator works
- List of all participating centers/research groups including the names of co-applicants

The project outline must be signed by all applicants.

2. Project title (**not more than 160 characters, including commas and spaces**)

3. Type of application. Please state whether this is a collaborative scientific project, a combination of a collaborative scientific project and a clinical trial (Phase I/II) or a Phase I/II clinical trial.

The letter of intent must be signed by the lead applicant.

Deutsche Krebshilfe
HELFEN. FORSCHEN. INFORMIEREN.

B. General Guidelines for all Project Outlines

Please submit **ten copies** of the project outline (**one unbound original and 9 bound copies of this**) to the office of the Deutsche Krebshilfe. Also send a PDF-Document of your project outline by e-mail (foerderung@krebshilfe.de).

The project outlines must be written in English.

Please follow the correct guideline for your project. There are three separate guidelines:
Guideline for a Collaborative Project (**p. 4)**
Guideline for a Combination of a Collaborative Project and Clinical Trial (Phase I/II) (**p. 7**)
Guideline for a Clinical Trial (Phase I/II) (**p. 11**)

To simplify the evaluation process for the reviewers:
- start the application with a table of contents and include the page numbers.
- address all points mentioned in the guidelines, repeating all section numbers/letters, as well as the complete section titles
- use 'Verdana', font size 10 and 1.2 line spacing.

Terms to be used in the application:
For consistency in the review process, only use the following terms for participating persons:
Lead applicant
Co-Applicant*
Co-operation Partner** Co-operation partners **do not** receive any funding.

***Co-applicants (as well as the lead applicant) cannot be employed in a foreign country, as **no funding from the German Cancer Aid is to be used outside of Germany**. Companies are not allowed as co-applicants. If companies offer material, we need a MTA (Material Transfer Agreement) for the full proposal. In the MTA it must clearly state that all rights to the results/findings of the project/trial belong to the applicant.
****Persons from foreign countries can participate only as co-operation partners.

The project outline must be signed by all applicants.

Please note:
The German Cancer Aid reserves the right to refuse and send back incomplete applications or applications, which have not been prepared according to the guidelines. Therefore, we urge you to address all points in the guidelines. **Please adhere strictly to the given page limits for each section.**

Deutsche Krebshilfe
HELFEN. FORSCHEN. INFORMIEREN.

Project Outline for Collaborative Projects:

The completed project outline is not to exceed 10 pages (excluding Appendices - CVs/Publication lists). Please adhere strictly to all given page limits for each section.

1. General Information

1.1 Project title (**not more than 160 characters**, including commas and spaces).

1.2 Lead applicant:

- First name, surname, academic degree
- Full name of the institution/department where the lead applicant works
- Postal address
- Telephone and fax number, e-mail address

1.3 Requested Funding Period (in months)

1.4 **Short summary and description** of the planned collaborative project
(not more than **2 pages - see below**)

Description of the overall concept and the main focal points of the project (**1 page**). Each subproject can here be very briefly described (**1 page**). **Do not include** charts, figures, graphs, images, footnotes, or references to other parts of your outline or to your publication lists.

1.5 **Graphic of Overall Concept** (**1 page**)

Graphic representation of the overall concept illustrating the interrelationship between all subprojects.

1.6 **Reapplications** (**0.5 page**)

If your collaborative project was already submitted in an earlier call and you are resubmitting your project, please explain what you have changed since the previous submission. If this does not apply to your application, please write 'N.A.'

1.7 **Translational aspects** of the proposed study
(not more than **0.5 page**)

What are the expected translational aspects of the project? How will scientific findings be translated into clinical practice?

1.8 **Long-term research objective(s)** of the planned collaborative project
(not more than **0.5 page**)

What are the special potential innovation and the long-term perspective for the project (bearing in mind the current status of the research)?

1.9 **Status of the planned collaboration** in national and international competition
(not more than **2 pages**)

- What are the important national and international developments (or lack of developments) in this area of research?

Deutsche Krebshilfe
HELFEN. FORSCHEN. INFORMIEREN.

- How does the planned collaboration fit into the present research landscape? To what extent does it go beyond the current status of this research?
- How does it differ from present research collaborations working on similar themes?

2. Tabular overview of subprojects (1-2 pages)
For each subproject, please give us the following:

- Number and title of the subproject
  For each applicant:
- First name, surname, academic degree
- Full name of the institution and department where the applicant works
- Third party funding - current and applied for - of all applicants, giving for each the project title (no acronyms), the (potential) source of funds, the duration (exact start and end date of the project in months) and the amount of the financial support. In case of a potential overlap with the current application, please give a short explanation (two sentences) below the table how the projects differ from each other. If this column would be too large, please list the third-party funding at a separate page (ordered by applicants).

Please use the following table:

Subproject Nr. and Title	**Applicants (with academic degree)**	**Institution**	**Third-party funding (current and applied for)**

3. Overview Financial plan (1 page)
Tabular overview of the estimated **total amount** of funding for each subproject and the total amount for the complete funding period. Please note that all contracts/agreements with third parties (for sequencing, analyses etc.) **go under the rubric 'Other'** and **not** 'Consumables'. If you are asked to submit a full proposal, cost estimates for these items and for investments from the third parties will be needed. **Please specify the investments, which you are applying for.**

Please use the following table **in landscape** format:

Subproject	Personnel*	Consumables	Animal Costs	Investments	Travel (For consortium meetings)	Other	Total
Total							

*For personnel costs, please give the title of the position(s) (e.g. Technician, Scientific Assistant, PhD Student, physician) and the salary grade in accordance with the collective agreement for federal state public employees (TV-L) - **Appendix 1**.

Deutsche Krebshilfe
HELFEN. FORSCHEN. INFORMIEREN.

Please also note the following when filling out the table:
For reasons of principle, the German Cancer Aid **does not** fund **overhead costs**.
Funds for **congress or convention trips cannot** be requested separately. However, if your project is approved by the German Cancer Aid, there is a possibility to re-allocate funds from consumables. Each subproject may re-allocate up to €1,000 (cost-neutral) per year for project-related congress trips with active participation. However, the re-allocated amount cannot exceed 10% of the total approved funding for consumables for the specific subproject.
Funds for **publication costs** also **cannot** be requested separately. Again, each subproject has the possibility to re-allocate funds from consumables, if funding is approved. Up to €750 per year can be re-allocated from the approved consumables. The financing of abstracts or reprints is excluded. The re-allocated sum, however, cannot exceed 10% of the total approved funding for consumables for the specific subproject.

4. Appendix: CVs and publication lists for all applicants
For each applicant:

- Current tabular CV (not more than **1 page**)
- Publication list of the **5** most important publications from the last 5 years in chronological order. All authors must be given for the citations in the publication lists. The abbreviation 'et al.' does not suffice.

Deutsche Krebshilfe
HELFEN. FORSCHEN. INFORMIEREN.

Project Outline for a combination of a collaborative project and a clinical trial (Phase I/II)

The completed project outline is not to exceed 15 pages (excluding Appendices - CVs/Publication lists). Please adhere strictly to all given page limits for each section.

1. General Information

1.1 Project title (**not more than 160 characters**, including commas and spaces).

1.2 **Lead applicant:**

- First name, surname, academic degree
- Full name of the institution at which the lead applicant works
- Postal address
- Telephone and fax number, email address

1.3 Requested funding period (in months)

1.4 **Short summary and description** of the planned collaborative project with a clinical trial (not more than **2 pages - see below**)

Description of the overall concept and the main focal points of the project (**1 page**). Each subproject can here be very briefly described (**1 page**). **Please include the clinical trial as a subproject. Do not include** charts, figures, graphs, images, footnotes, or references to other parts of your outline or to your publication lists.

1.5 Study Synopsis of the clinical trial (**1-3 pages**)

Give a synopsis of your planned clinical trial, **using this tabular form**:

Lead Applicant/Co-applicants	Name, address, telephone, fax, e-mail If there are multiple applicants, the principal investigator/coordinating investigator of the trial will assume responsibility for conducting the clinical trial and **should be listed first.**
Requested Funding Period	In months
Participating Centers	Name the participating centers involved in your trial
Title of study	(maximum 160 characters, including commas and spaces)
Condition	The medical condition being studied
Objective(s)/Hypotheses	Which principal research questions are to be addressed? Clearly specify the primary hypotheses of the trial that determine sample size calculation.
Intervention(s)	Description of the experimental and the control treatments or interventions, as well as dose and mode of application. For diagnostic tests or procedures, the index test and the reference procedure (gold standard) should be described. Experimental intervention / index test: Control intervention / reference test: Follow-up per patient: Duration of intervention per patient:

	Number of doses:
Key inclusion,exclusion and withdrawal criteria	Key inclusion criteria: Key exclusion criteria: Key withdrawal criteria:
Conditions for discontinuing the trial	Explain what criteria will be used to determine if the trial should be discontinued.
Outcome(s)	Primary efficacy endpoint: Key secondary endpoint(s): Assessment of safety:
Study design	e. g. Phase I or II or I/II, basket, umbrella, randomized/non-randomized, type of masking (single, double, observer blind), type of controls (active/placebo), parallel group/crossover, prognostic, diagnostic
Statistical analysis	Efficacy / test accuracy: Description of the primary efficacy / test accuracy analysis and population: Safety: Secondary endpoints:
Trial Drug(s)*	Name the trial drug(s) and your supply source (e.g. name of the pharmaceutical company, over the counter - pharmacy).
Total Patient Numbers	To be assessed for eligibility (n = ...) To be allocated to trial (n = ...) To be analyzed (n = ...)
Trial duration (in months)	Duration of the entire trial (first patient in to last patient out, recruitment period).

***Please be aware, that should the drug(s) come from a pharmaceutical company, an MTA (Material Transfer Agreement will be needed for the full proposal (please see p. 3). The trial cannot be co-financed by a pharmaceutical company.**

1.6 **Graphic of Overall Concept (1 page)**

Graphic representation of the overall concept illustrating the interrelationship between all subprojects (including the clinical trial).

1.7 **Reapplications (0.5 page)**

If your project was already submitted in an earlier call and you are resubmitting your project, please explain what you have changed since the previous submission. If this does not apply to your application, please write 'N.A.'

1.8 **Translational aspects** of the proposed study
(not more than **0.5 pages**)

What are the expected translational aspects of the project? How will scientific findings be translated into clinical practice?

Deutsche Krebshilfe
HELFEN. FORSCHEN. INFORMIEREN.

1.9 **Long-term research objective(s)** of the planned collaborative project with a clinical trial (not more than **0.5 pages**)

What are the special potential innovation and the long-term perspective for the project (bearing in mind the current status of the research)?

1.10 **Status of the planned collaboration in national and international competition** (not more than **2 pages**)

- What are the important national and international developments (or lack of developments) in this area of research?
- How does the planned collaboration fit into the present research landscape? To what extent does it go beyond the current status of this research?
- How does it differ from present research collaborations working on similar themes?

2. Tabular overview of subprojects (1-2 pages)
List the clinical trial as one of the subprojects. For each subproject, please give us the following:

- Number and title of the subproject
  For each applicant:
- First name, surname, academic degree
- Full name of the institution and department where the applicant works
- Third party funding - current and applied for - of all applicants, giving for each the project title (no acronyms), the (potential) source of funds, the duration (exact start and end date of the project in months) and the amount of the financial support. In case of a potential overlap with the current application, please give a short explanation (two sentences) below the table how the projects differ from each other. If this column would be too large, please list the third-party funding at a separate page (ordered by applicants).

Please use the following table:

Subproject Nr. and Title	**Applicants (with academic degree)**	**Institution**	**Third-party funding (current and applied for)**

3. Overview Financial plan (1 page) - Use Appendix 2
Tabular overview of the estimated **total amount** of funding for each subproject/clinical trial and the total amount for the complete funding period. Please note that all contracts/agreements with third parties (for sequencing, analyses etc.) **go under the rubric 'Other'** and **not** 'Consumables'. If you are asked to submit a full proposal, quotes for these items and for investments **from the third parties** will be needed.

Please use the table: **Appendix 2 in landscape format.**

Please also note the following when filling out the table:
For reasons of principle, the German Cancer Aid **does not** fund **overhead costs**.

Deutsche Krebshilfe
HELFEN. FORSCHEN. INFORMIEREN.

Funds for **congress or convention trips cannot** be requested separately. However, if your project is approved by the German Cancer Aid, there is a possibility to re-allocate funds from consumables. Each subproject may re-allocate up to €1,000 (cost-neutral) per year for project-related congress trips with active participation. However, the re-allocated amount cannot exceed 10% of the total approved funding for consumables for the specific subproject.
Funds for **publication costs** also **cannot** be requested separately. Again, each subproject has the possibility to re-allocate funds from consumables, if funding is approved. Up to €750 per year can be re-allocated from the approved consumables. The financing of abstracts or reprints is excluded. The re-allocated sum, however, cannot exceed 10% of the total approved funding for consumables for the specific subproject.

4. Appendix: CVs and publication lists for all applicants

For each applicant:

- Current tabular CV (**1 page**)
- Publication list of the 5 most important publications from the last 5 years. All authors must be given for the citations in the publication lists. The abbreviation 'et al.' does not suffice.

Deutsche Krebshilfe
HELFEN. FORSCHEN. INFORMIEREN.

Project Outline for clinical studies (Phase I/II)

The completed project outline is not to exceed 10 pages (excluding Appendices - CVs/Publication lists). Please adhere strictly to all given page limits for each section.

An application can be made to the Deutsche Krebshilfe for a research grant for performing non-commercial science-driven cancer therapy studies ('Investigator Initiated Trials'). But please note the following:

- If a study is supported by the Deutsche Krebshilfe, the only permissible form of support from industrial partners is the free provision of the test substance. The project management must disclose financial support for the study to the Deutsche Krebshilfe in the application and at any time during the course of the study. Written agreements with industrial partners must be attached to the application documents. The project management must have exclusive ownership of all data. The design, conduct, recording and reporting of the clinical trial has to be under the control of the project management.
- Outlines and applications for funding study projects cannot be included in the evaluation procedure if recruitment has started before application, or is to be started during the application procedure.
- The outlines **must** be written according to the following template:

1. Study Synopsis (1-3 pages)

Give a synopsis of your planned study, **using this tabular form**:

Lead Applicant/Co-applicants	Name, address, telephone, fax, e-mail If there are multiple applicants, the principal investigator/coordinating investigator of the trial will assume responsibility for conducting the clinical trial and **should be listed first.**
Requested Funding Period	In months
Participating Centers	Name the participating centers involved in your trial
Title of study	(maximum 160 characters, including commas and spaces)
Condition	The medical condition being studied
Objective(s)/Hypotheses	Which principal research questions are to be addressed? Clearly specify the primary hypotheses of the trial that determine sample size calculation.
Intervention(s)	Description of the experimental and the control treatments or interventions, as well as dose and mode of application. For diagnostic tests or procedures, the index test and the reference procedure (gold standard) should be described. Experimental intervention / index test: Control intervention / reference test: Follow-up per patient: Duration of intervention per patient:

Deutsche Krebshilfe
HELFEN. FORSCHEN. INFORMIEREN.

	Number of doses:
Key inclusion,exclusion and withdrawal criteria	Key inclusion criteria: Key exclusion criteria: Key withdrawal criteria:
Conditions for discontinuing the trial	Explain what criteria will be used to determine if the trial should be discontinued.
Outcome(s)	Primary efficacy endpoint: Key secondary endpoint(s): Assessment of safety:
Study design	e. g. Phase I or II or I/II, basket, umbrella, randomized/non-randomized, type of masking (single, double, observer blind), type of controls (active/placebo), parallel group/crossover, prognostic, diagnostic
Statistical analysis	Efficacy / test accuracy: Description of the primary efficacy / test accuracy analysis and population: Safety: Secondary endpoints:
Trial Drug(s)*	Name the trial drug(s) and your supply source (e.g. name of the pharmaceutical company, over the counter - pharmacy).
Total Patient Numbers	To be assessed for eligibility (n = ...) To be allocated to trial (n = ...) To be analyzed (n = ...)
Trial duration (in months)	Duration of the entire trial (first patient in to last patient out, recruitment period).

***Please be aware, that should the drug(s) come from a pharmaceutical company, an MTA (Material Transfer Agreement will be needed for the full proposal (please see p. 3). The trial cannot be co-financed by a pharmaceutical company.**

1.1 **Reapplications (0.5 page)**
If your application was submitted in an earlier call and you are resubmitting your project, please explain what you have changed since the previous submission. If this does not apply to your application, please write 'N.A.'

1.2 **Intervention scheme/trial flow/Clinical trial schedule (1 page)**
Describe the intervention scheme and give a schematic diagram (flow chart) of design, procedures and stages (trial schedule, clinical follow-up plan).

1.3 **Frequency and scope of study visits (0.5 page)**
What is the proposed frequency and scope of study visits and, if applicable, the duration of post-trial follow-up? Please also give a table with time points of visits and procedures per time-point. Specify items to be recorded CRF per procedure.

2. The medical problem (0.5 page)

- Which medical problem is to be addressed?
- What is the novel aspect of the proposed trial?

Deutsche Krebshilfe
HELFEN. FORSCHEN. INFORMIEREN.

- Which principal research questions are to be addressed? Bring them into order indicating major and minor motivations / starting hypotheses of the investigation planned.

2.1 **Evidence (0.5 page**)

Set your trial into perspective. This section should give the detailed background of the starting hypotheses and the feasibility of the trial.

- Which trials have been conducted either by you or by others? What is the relevance of their results? Give references to any relevant systematic review(s) and/or (your own) pilot studies, feasibility studies, relevant previous/ongoing trials, case reports/series. State what your study adds to the overall evidence, in the context of previous work. Include a description of how you searched for evidence (databases, search terms, limits) and how you assessed its quality - i.e., how you selected and how you combined the evidence. If any relevant evidence is not included, the project will not be funded.

2.2 **The need for a trial (0.5 page**)

- How significant is the trial in terms of its potential impact on relieving the burden of disease and/or improving human health?
- What impact will the results have on clinical practice?
- How will the individual patient benefit from the trial? Describe any potential commercial interest of a company in the results of the trial or explain why no such interest exists. If a company has direct commercial interest in the results of the trial, funding of the project could be rejected.

2.3 **Feasibility of recruitment (0.5 page**)

What is the evidence that the intended recruitment rate is attainable (e.g. pilot study)? Describe the data you used to assess the potential for recruiting the required number of suitable subjects.

3. Statistical analysis (0.5 page)

- What is the proposed strategy of statistical analysis?
- What is the strategy for analyzing the primary outcome? If interim analyses are planned, please specify.
- Are there any subgroup analyses?

4. Ethical considerations (0.5 page)

Briefly discuss the acceptability of the risk incurred by the individual participant versus the potential benefit for the participant/population concerned.

5. Overview Financial plan (1 page) - Use Appendix 3

Tabular overview of the estimated **total amount** of funding for the clinical trial. Please note that all contracts/agreements with third parties (for sequencing, analyses etc.) **go under the rubric** '**Other**' and **not** 'Consumables'. If you are asked to submit a full proposal, quotes for these items and for investments **from the third parties** will be needed.

Please use the table: **Appendix 3** in **landscape format.**

Please <u>also</u> note the following when filling out the table:

Deutsche Krebshilfe
HELFEN. FORSCHEN. INFORMIEREN.

For reasons of principle, the German Cancer Aid **does not** fund **overhead costs**.
Funds for **congress or convention trips cannot** be requested separately. However, if your project is approved by the German Cancer Aid, there is a possibility to re-allocate funds from consumables. Up to €1,000 (cost-neutral) per year for project-related congress trips with active participation may be re-allocated. However, the re-allocated amount cannot exceed 10% of the total approved funding for consumables for the specific subproject.
Funds for **publication costs** also **cannot** be requested separately. Again, the re-allocation of funds from consumables, if funding is approved, is possible. Up to €750 per year can be re-allocated from the approved consumables. The financing of abstracts or reprints is excluded. The re-allocated sum, however, cannot exceed 10% of the total approved funding for consumables for the specific subproject.

6. Appendix: CVs, publication lists and third-party funding of all applicants
For each applicant:

- Current tabular CV (**1 page**)
- Publication list of the 5 most important publications from the last 5 years. All authors must be given for the citations in the publication lists. The abbreviation 'et al.' does not suffice.
- Third party funding - current and applied for - of all applicants, giving for each the project title (no aconyms), the (potential) source of funds, the duration (exact start and end date of the project in months) and the amount of the financial support. In case of a potential overlap with the current application, please give a short explanation (two sentences) below the table how the projects differ from each other. If this column would be too large, please list the third-party funding at a separate page (ordered by applicants).

Additional Comments

- No legal claim for funding can be derived from the submission of an application. The applicant has no claim that a submitted application should be returned.
- The Deutsche Krebshilfe retains the right to check for duplicate funding by providing other external funding sources with the applicant's information (name, theme and objective of the project).
- The acceptance of a research grant obligates the funding recipient to comply with the rules of Good Scientific Practice. The rules of Good Scientific Practice are described in detail in the user guidelines for research funds from the German Research Foundation (DFG preprints 2.01 and 2.02). In the event of scientific misbehavior, sanctions can be concluded. In particular, scientific misbehavior is present when false information is provided deliberately or with gross negligence in a context of considerable scientific importance, or the intellectual property of others is violated or their research work is impaired. The circumstances of the individual case are always decisive.

Deutsche Krebshilfe
HELFEN. FORSCHEN. INFORMIEREN.

Contact

Your contacts are:
Dr. Matthias Serwe (Tel.: 0228/72990-223, e-mail: serwe@krebshilfe.de)
Kim Tiede (Tel.: 0228/72990-217, e-mail: tiede@krebshilfe.de)
Dr. Laura Planko (Tel.: 0228/72990-224, e-mail: planko@krebshilfe.de).

Last revised: 02/2018 (changes to last guidelines are highlighted in grey)

Deutsche Krebshilfe
HELFEN. FORSCHEN. INFORMIEREN.

Appendix 1: Average Personnel Wages of the DKH 2017

TV-L	DKH ab 10.2017 p. a.
E 1	**30.500,00 €**
E 2	**37.400,00 €**
E 3	**39.900,00 €**
E 4	**41.400,00 €**
E 5	**43.200,00 €**
E 6	**44.900,00 €**
E 7	**46.200,00 €**
E 8	**48.600,00 €**
E 9	**53.300,00 €**
E 10	**59.900,00 €**
E 11	**63.000,00 €**
E 12	**68.000,00 €**
Doktorand E 13, 65 %	**46.605,00 €**
E 13	**71.700,00 €**
E 14	**77.300,00 €**
E 15	**85.000,00 €**
E 15Ü	**106.300,00 €**
Professuren	
W2	**97.200,00 €**
W3	**107.300,00 €**

Ärzte	DKH ab 10.2017 p. a.	DKH ab 10.2017 pauschal p. a.
Ä1/1	74.800,00 €	
Ä1/2	79.000,00 €	
Ä1/3	82.100,00 €	
Ä1/4	87.300,00 €	
Ä1/5	93.600,00 €	
Ä1/6	96.000,00 €	
Ä1/1-6		**85.500,00 €**
Ä2/1	98.700,00 €	
Ä2/2	107.000,00 €	
Ä2/3	114.300,00 €	
Ä2/4	118.400,00 €	
Ä2/5	120.600,00 €	
Ä2/6	123.700,00 €	
Ä2/1-4		**113.800,00 €**
Ä3/1	123.700,00 €	
Ä3/2	130.900,00 €	
Ä3/3	141.300,00 €	
Ä3/1-3		**132.000,00 €**
Ä4/1	145.500,00 €	
Ä4/2	155.900,00 €	
Ä4/3	164.100,00 €	
Ä4/1-3		**155.200,00 €**
Hilfskräfte		
Stud. HK (20 Std./Woche)	12.000,00 €	
Wiss. HK (20 Std./Woche)	18.000,00 €	

Deutsche Krebshilfe
HELFEN. FORSCHEN. INFORMIEREN.

Appendix 2: Overview Financial Plan: Combination of a Collaborative Project and a Clinical Trial (Phase I/II)

Subproject	Personnel	Consumables	Animal Costs	Investments	Travel	Other			**Total**
Subproject 1									
Subproject 2									
	Personnel*	Documentation	Monitoring**	Pharmacovigilance	Patient Insurance	Other	Trial Drug	Fees (Ethic committees and Federal Authorities)	
Subproject X Clinical Trial									
Total									

Note:
***For **personnel costs**, please give the title of the position(s) (e.g. Technician, Scientific Assistant, PhD Student, physician) and the salary grade in accordance with the collective agreement for federal state public employees (TV-L) - **Appendix 1**.
****Monitoring costs** should **include** travel costs for patients. If the monitoring costs are calculated by case numbers, the required personnel for monitoring can be included under monitoring costs. If this is the case, please give a short explanation for this and mention the estimated money calculated per case (1-2 sentences).

Deutsche Krebshilfe
HELFEN. FORSCHEN. INFORMIEREN.

Appendix 3: Overview Financial Plan: Clinical Trial (Phase I/II)

	Personnel*	**Documentation**	**Monitoring****	**Pharmacovigilance**	**Patient Insurance**	**Other**	**Trial Drug**	**Fees** (Ethic committees and Federal Authorities)	**Total**
Clinical Trial									
Total									

Note:
***For **personnel costs**, please give the title of the position(s) (e.g. Technician, Scientific Assistant, PhD Student, physician) and the salary grade in accordance with the collective agreement for federal state public employees (TV-L) - **Appendix 1**.
****Monitoring costs** should **include** travel costs for patients. If the monitoring costs are calculated by case numbers, the required personnel for monitoring can be included under monitoring costs. If this is the case, please give a short explanation for this and mention the estimated money calculated per case (1-2 sentences).